PURE Bioscience Appoints Darin Zehr to Board of Directors
May 06 2024 - 1:00PM
Business Wire
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or
“we”), creator of the patented non-toxic silver dihydrogen citrate
(SDC) antimicrobial, today reported the appointment of Darin Zehr
to its Board of Directors, effective as of May 1, 2024.
Mr. Zehr joins as an independent director and will also serve as
a member of PURE’s Audit Committee and Compensation Committee. Mr.
Zehr brings extensive experience working in the food industry.
Since 1990, he has held various roles in food quality and safety,
sanitation, and operations management. He is the General Manager of
Commercial Food Sanitation LLC (CFS). CFS, an Intralox Company, is
a global food safety consulting and training organization that
works across all food industry segments and has operations in North
and South America, Europe, Asia, and Australia. Prior to this role,
Mr. Zehr spent 22 years with Kraft Foods where he held numerous
roles in operations, including Area Sanitation Manager, Business
Unit Manager, and Plant Manager. He is Treasurer of the Board of
Directors for Beaver Camp, a non-profit Christian Camping
establishment, a former board member of the New York State Cheese
Manufacturer’s Association, and former board member of the Lewis
County General Hospital. Mr. Zehr received a Bachelor of Science
degree in Chemistry from The State University of New York (SUNY) at
Oswego. He lives in Northern New York with his wife of 30 years and
has three adult children.
Mr. Zehr said, “I am excited to join the Board of Directors and
engage with this great team supporting a product line that adds so
much value.”
Robert Bartlett, Chief Executive Officer, said, “Mr. Zehr is a
welcomed addition and we are honored to have his valuable food
industry experience and insights on our Board.”
About PURE Bioscience, Inc.
PURE is focused on developing and commercializing our
proprietary antimicrobial products primarily in the food safety
arena. We provide solutions to combat the health and environmental
challenges of pathogen and hygienic control. Our technology
platform is based on patented, stabilized ionic silver, and our
initial products contain silver dihydrogen citrate, better known as
SDC. This is a broad-spectrum, non-toxic antimicrobial agent, and
formulates well with other compounds. As a platform technology, SDC
is distinguished from existing products in the marketplace because
of its superior efficacy, reduced toxicity and mitigation of
bacterial resistance. PURE’s mailing address of 771 Jamacha Rd.
#512, El Cajon, California 92019 (San Diego County area) serves as
its official address for all business requirements. Additional
information on PURE is available at www.purebio.com.
Forward-looking Statements: Any statements contained in
this press release that do not describe historical facts may
constitute forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. Statements in
this press release, including quotes from management, concerning
the Company’s expectations, plans, business outlook, future
performance, future potential revenues, expected results of the
Company’s marketing efforts, the execution of contracts under
negotiation and any other statements concerning assumptions made or
expectations as to any future events, conditions, performance or
other matters, are “forward-looking statements.” Forward-looking
statements inherently involve risks and uncertainties that could
cause our actual results to differ materially from any
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, the Company’s
failure to implement or otherwise achieve the benefits of its
proposed business initiatives and plans; acceptance of the
Company’s current and future products and services in the
marketplace, including the Company’s ability to convert successful
evaluations and tests for PURE Control and PURE Hard Surface into
customer orders and customers continuing to place product orders as
expected and to expand their use of the Company’s products; the
Company’s ability to maintain relationships with its partners and
other counterparties; the Company’s ability to generate sufficient
revenues and reduce its operating expenses in order to reach
profitability; the Company’s ability to raise the funding required
to support its continued operations and the implementation of its
business plan; the ability of the Company to develop effective new
products and receive required regulatory approvals for such
products, including the required data and regulatory approvals
required to use its SDC-based technology as a direct food contact
processing aid in raw meat processing and to expand its use in OLR
poultry processing; competitive factors, including customer
acceptance of the Company’s SDC-based products that are typically
more expensive than existing treatment chemicals; dependence upon
third-party vendors, including to manufacture its products; and
other risks detailed in the Company’s periodic report filings with
the Securities and Exchange Commission (the SEC), including its
Form 10-K for the fiscal year ended July 31, 2023, Form 10-Q for
the fiscal first quarter ended October 31, 2023, and Form 10-Q for
the fiscal second quarter ended January 31, 2024. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506415354/en/
Mark Elliott, VP Finance PURE Bioscience, Inc. Phone:
619-596-8600 ext.: 116